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Inflammatory bowel diseases are strongly associated with
carcinomas of the colorectum and, in patients with co-existing
primary sclerosing cholangitis, with cholangiocarcinoma. The
knowledge of these associations has provided impetus for
researchers and clinicians to study the pathogenesis of those
cancers, and to develop strategies for managing the elevated
risk of those cancers in patients with IBD. In contrast, much
less is known about associations between IBD and other more
rare cancers of the lower intestinal tract.
We held two workshops to plan and develop a work
program to review the current state of knowledge on small
bowel adenocarcinoma, ileo-anal pouch and rectal cuff
cancer, and anal/perianal fistula cancers in IBD patients.
Authors worked together to review and summarize the
literature and to identify the key knowledge gaps that could
be filled through collaborative research through ECCO.
2. Small bowel adenocarcinoma in
Crohn's disease
2.1. Epidemiology
Small bowel malignancies represent 2% of all cancers.1,2
Adenocarcinoma accounts for 50% of small bowelmalignancies,followed by neuroendocrine tumors, lymphoma and sarcoma.3
Since Ginzburg et al.4 first described the association of Crohn's
disease (CD) and small bowel adenocarcinoma (SBA) in 1956,
several case reports, case series and some case–control studies
have been reported. Patients affected with CD are at higher
risk of developing SBA.5–20 Three meta-analyses have assessed
the standardized incidence ratio (SIR) of SBA in patients with
CD from population-based or referral center case series. They
found that pooled SIRs were 27.1 (95% CI 14.9–49.2), 28.4 (95%
confidence interval, 14.46–55.66), and 33.2 (15.9–60.9)
respectively.20–22 One study, based upon a tertiary referral
center, has found that the cumulative risk is 0.2% and 2.2% at
10 and 25 years since diagnosis, respectively.13,16
International case–control studies are advisable and the
development of specific National and International Cancer
Registries is to be encouraged.2.2. Pathogenesis
The pathogenesis of SBA in CD is poorly defined. Much of the
current understanding of the molecular alterations involved
in the development of neoplasia in IBD comes from studies of
patients with ulcerative colitis (UC) who develop colorectal
carcinoma, also considered to be valid in CD. SBA is usually
found in inflammatory areas, which suggests that the
sequence inflammation–dysplasia–carcinoma is valid.
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 2.2.1. The implication of histological patterns
In the majority of the reported cases of SBA in CD, there is
no description of histological subtype or molecular alter-
ations, rending an insight on carcinogenic pathways difficult.
SBA in CD shares some histological and molecular character-
istics with colorectal carcinomas in UC. In a series of SBA
published by Palascak-Juif et al., the rate of mucinous
adenocarcinoma in CD was higher (30% vs 10%) and signet
cell variety unique, when compared to small bowel adeno-
carcinoma de novo (Table 1).16
2.2.2. Microsatellite instability
The data on microsatellite instability (MSI) in small bowel
carcinomas are fewer than for colorectal cancer, with
conflicting data published. One study reports the incidence
of MSI as 20%.23 However, another study concludes that
MSI is less common in CD than UC and this may reflect
differences in cancer risk between these two forms of IBD.24
Further studies examining the expression and the presence
or absence of mutations in these genes may provide insight
into the mechanisms underlying the development of micro-
satellite alterations in the setting of IBD.
2.2.3. c-K-ras mutations
Mutations of K-ras are accepted as common in colitis-
associated colorectal neoplasia and can occur early in
neoplastic progression. Rashid et al. found mutations in
c-K-ras codons 12 and 13 in 43% of Crohn's associated with
SBA. They also found that carcinomas with contiguous
adenomas have the same c-K-ras mutation. Finally, they
showed that small intestinal neoplasia is characterized by
accumulation of multiple genetic alterations during progression
through an adenoma–carcinoma sequence and an dysplasia–
carcinoma sequence.25
2.2.4. APC gene
In contrast to sporadic colorectal carcinoma, the allelic
losses of 5q (APC gene) and DCC regions (deleted in colon
cancer gene region on q18) are uncommon events in CD and
sporadic SBA, suggesting that genetic pathways involved in
carcinomas of the small intestine are not identical to the
colorectum.26,27
In conclusion, some of the available data indicate that
the sequence inflammation–dysplasia–cancer might beTable 1 Comparison between SBA in CD and SBA de
novo.9,13,43,51,56
SBA in CD SBA de novo
Median age at SBA
diagnosis, years
48 65
Gender M N F M = F
Duration of CD before
SBA diagnosis, years
15 –
Preoperative diagnosis, % 3.1–13.8 50
Localization, % I 99–J 1 J 40–I 30–M 30
Stage IV at diagnosis, % Up to 38 Up to 42.5
Signet ring cells, % Up to 35 –
SBA: small bowel adenocarcinoma; CD: CD; M: male; F: female;
I: ileum; J: jejunum; M: mid small bowel.involved in the pathogenesis of SBA. The rarity of this
neoplasm renders relevant study of pathogenesis difficult.
2.3. Risk factors
Risk factors associated with SBA include
CD,2,5–7,9,12–14,16,18,20,28–31 celiac disease, hereditary gas-
trointestinal cancer syndromes, immunodeficiency states
and autoimmune disorders2,32; alcohol, cigarette smoking,
and dietary habits (red meat, smoked, and salt-cured
foods).29,33 The consumption of bread, pasta, rice, and
sugar33,34 have been also reported as correlated with SBA.
Risk factors for developing SBA in CD are less well
defined, although several have been proposed:
- disease-related: distal jejunal/ileal localization, strictures and
chronic penetrating disease, duration of disease
- patient-related: young age at diagnosis, male sex
- drug-related: corticosteroids, azathioprine, 6-mercaptopurine,
anti-TNF-alpha agents
- surgery-related: small bowel bypass loops, strictureplasties,
absence of resection
- environmental: occupational hazards/exposure to halogenated
aromatic compounds with aliphatic amines, asbestos, and solvents.
All these factors have been variously proposed to have a
carcinogenic potential.2,5–7,9,12–14,16,18–20,28,30,31,35 Most are
debated and results from single series are contrasting.
Concerning surgery, the role of strictureplasty in promot-
ing SBA is unclear and not widely accepted.36 The reason for
SBA in strictureplasties could be due either to the develop-
ment of carcinoma in an area of bowel previously treated by
strictureplasty or to the potential for missing a malignancy
at the time of strictureplasty.36–38
2.4. Diagnosis
Early diagnosis is the key to achieve successful treatment of
SBA in CD. Dosset et al.39 were able to diagnose preopera-
tively only 3.1% of SBA. A more recent study was more
optimistic, but preoperative diagnosis did not even reach
14% in CD patients.40 Furthermore, nearly 30–35% of
patients had metastatic disease (Stage IV) and 55% were
found with positive nodes at diagnosis.32,33,40
2.4.1. Symptoms
Symptoms of SBA are nonspecific32 and are hard to
distinguish from relapse of CD.16,19,33,39,40 Authors agree
that two indicators may guide physicians and raise suspicion
of SBA: intestinal obstruction not relieved by medical
management and abrupt onset with severe symptoms after
a period of quiescent disease.16,19,39–41
2.4.2. Imaging and endoscopy
Investigations also rarely succeed in differentiating
active CD from SBA because strictures and masses are
frequently seen in CD, due to its common complications.19,32
Radiological investigations such as CT, MR and barium
radiography can detect strictures and masses but do not
allow sampling of suspect areas.31 Similarly, small bowel
capsule endoscopy does not allow tissue sampling and does
not accurately localize and grade lesions.42
22 L. Egan et al.
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 Most SBAs are located in the terminal or distal ileum and
may be reached by a colonoscope, allowing mucosal biopsy for
accurate diagnosis. For more proximal lesions, double balloon
enteroscopy represents a promising tool for small bowel
examination in patients with CD suspected of SBA. It is
particularly useful in established CD as adhesions may limit
other examinations (i.e. single balloon enteroscopy).42 How-
ever, drawbacks must be taken into account: double balloon
enteroscopy does not allow extra-intestinal assessment of the
disease and requires extensive expertise and anesthesia42;
also “in a patient with stricturing active CD, there appears to
be a higher risk of complications” (EL4, RG C, Statement 3F,
ECCO–OMED consensus on small bowel endoscopy in IBD).42
If the surgeon suspects that a patient is at higher risk of
SBA (i.e. for presenting symptoms and/or duration of CD), it
is useful to perform an intraoperative histologic examina-
tion. Intraoperative enteroscopy may also be useful because
it detects lesions inaccessible to conventional endoscopy,
undetected in more than half of the patients prior to
surgery.43–45 In the future, the usefulness of positron
emission tomography CT in identifying, localizing and
differentiating between CD and SBA should be tested.
In conclusion, as early diagnosis is of critical significance
for the survival of the patient, clinicians should consider
exploratory laparotomy as a possible diagnostic and thera-
peutic approach in cases of CD patients with suspected SBA. by guest on February 23, 2016
co-jcc.oxfordjournals.org/2.5. Treatment
Although there are very few data on the management of
dysplasia, we encourage surgical resection whether low grade
or high grade, when detected by endoscopic small bowel
biopsies in areas of inflammation. Indeed, an association of
dysplasia with synchronous SBA has been reported in surgical
specimens46 compatible with a dysplasia–carcinoma sequence.
Similar to SBA de novo, surgery is the mainstay of
treatment for SBA in CD, and is best performed as a radical
resection. However, most SBAs in CD are diagnosed intraop-
eratively39,40 and half of the carcinomas are not even
suspected at operation and are diagnosed only upon
microscopic examination in some series.47,48 Early detection
of SBA is therefore crucial to achieve radical treatment, and
CD patients developing SBA commonly have a long history of
repeated hospitalizations during which diagnosis of SBA was
often overlooked and surgery was delayed.40
Both Solem et al.19 and the GETAID35 suggested that
prolonged salicylate administration can decrease the risk of
SBA in patients with longstanding ileal CD. The latter study
also reported that surgery has a very important role in the
potential prevention of SBA, thus advocating a role for
prophylactic surgery.35 In agreement with this observation,
other authors reported that surgical resection can remove
chronic inflamed segments which are highly associated with
SBA development in these patients, and should be advocated
especially in patients followed up for more than 10 years.16
SBA is rare and the number of patients to resect to prevent
SBA is likely to be high, even in patients with longstanding
CD lesions. By analogy with UC, it can be suggested to
restrict prophylactic small bowel resection to patients with
dysplasia on endoscopic biopsies. This suggested strategy
still has to be validated.16,35,40Operation for SBA in CD is the same as SBA de novo. Surgery
should aim to obtain free resection margins, implying wide
resection, and resection of a wedge of mesentery is necessary
to capture the draining lymph node basin. Tumors with
extensive local disease, metastases to multiple regional/
distant lymph nodes and/or the liver/peritoneal surface may
be unresectable. For tumors of the jejunum and proximal
ileum, wide local excision with lymphadenectomy is the
procedure of choice.49–51 The number of lymph nodes
retrieved has been used as a measure of quality in surgical
care of bowel malignancies,52 but the optimal harvest of
nodes for SBA has yet to be defined. Nicholl et al.53, by
applying lymph node recovery as a surrogate for adequate
surgical resection, suggested that SBA appears to be surgically
undertreated. They proposed a threshold of 10 nodes to define
an adequate resection, and found that majority of patients
have few nodes resected, even in early-stage disease.
Adequate mesenteric resection is limited by the proxim-
ity of the nodes or tumor to the superior mesenteric
artery.31 Pancreaticoduodenectomy may be required for
tumors in the second or third portion of the duodenum.1,31
Segmental resection of duodenal tumors generally corre-
lates with a better overall survival compared with a Whipple
procedure54 although this observation is not confirmed in a
series of 37 patients operated on for SBA at the Cleveland
Clinic, where increased survival was found in patients who
underwent Whipple resection.1
Distal ileal lesions may require ileocolectomy/right
hemicolectomy31 to remove all nodes draining the tumor
site. Patients who are considered incurable may undergo
palliative resections, bypass procedures or double-balloon
enteroscopy can be advocated to place self-extendable
stents in stenosed bowel lumen with palliative intent.55
For metastatic disease and incomplete resection some
authors advocated the use of radiotherapy or chemotherapy
for SBA,31,50 but very few patients receive radiotherapy as
part of their primary treatment.50,56,57 Japanese investigators
also explored the use of intraoperative radiotherapy, where a
single dose of radiation can be given to a tumor bed with
residual microscopic or macroscopic disease while shielding
nearby organs.58 5-Fluorouracil is the most common chemo-
therapy agent used, either as a single agent or in combination
with other agents, including doxorubicin, cisplatin, levami-
sole, and mitomycin.49,50,56,57,59,60 Average overall survival
with metastatic disease is reported to increase from 9–
11 months to 17–20 months12 with less than 5% of patients
surviving longer than 2 years in available series.12,49,50,56,59,60
There are several phase I and II trials on-going evaluating
various radiotherapy and chemotherapy regimens for SBA.
Patients affected with SBA in CD should be encouraged to
enter future or on-going clinical trials.2.6. Prognosis
SBA has an aggressive nature, and survival is poor.61–63 The
reported 5-year survival rates range between 20% and
30%.2,61 Lymph node involvement is reported to reduce
5-year survival from 60–70%51 to 12–14%.51,64
Survival rates for SBA complicating CD are reported to be
lower compared to de novo SBA, with 30–60% mortality at
2-year follow-up; one series found a 2-year survival of as low
23Non-colorectal intestinal tract carcinomas in inflammatory bowel disease
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 as 9%.16,18,19,65,66 Nevertheless, Agrawal et al.67 reported
survival up to 10 years for multiple patients initially diagnosed
with stage II and III SBAs. The possibility of aggressive surgical
care for early-stage SBA should not be dismissed.
3. Ileo-anal pouch and rectal cuff carcinoma
Restorative proctocolectomy with ileal pouch-anal anasto-
mosis is the preferred surgical management of patients with
UC who do not respond to intense medical treatment or who
develop cancer or dysplasia. Because of the removal of the
whole large bowel, this operation substantially reduces the
risk of UC-associated dysplasia/neoplasia, although it does
not completely abolish the risk of neoplasia of the pouch or
rectal cuff.
In recent years, it has become apparent that the
development of cancer in the pouch, although quite rare, is
a reality. Various aspects concerning epidemiology, patho-
genesis, diagnosis, and prevention strategies have been
investigated. However, the available data are not enough to
allow drawing firm conclusions and more work is necessary in
order to accomplish this task.
3.1. Epidemiology
3.1.1. Carcinoma
Pouch-related carcinomas have been described with
increasing frequency since the first report in 1984 in a
number of case-reports and small case-series. During the last
two years, three reviews have collected this literature
aiming to analyze the clinicoepidemiological features, risk
factors and prevention strategies for pouch carcinoma.68–70
In a recently published review including 12 retrospective
series and 15 case-reports of IBD-associated colorectal cancer
patients and those undergoing restorative proctocolectomy
surgeries from 1984 to 2010, the authors found 43 cases of
pouch-related cancers, of which 32 were located in the anal
transitional zone (ATZ) and 11 in the pouch body. Most of the
cases were adenocarcinomas with some of them being
squamous cell carcinomas. Sixteen cases were described in
retrospective series, 1 case was from a prospective study, and
26 from case-reports. Thirty patients underwent mucosectomy
and 13 had stapled anastomoses.70
Alessandroni et al. described 50 reported cases in the
international literature. Twenty-five of these cases appeared
after mucosectomy and hand-sewn anastomosis and 25 after
stapling technique. In 48% of them, dysplasia or cancer was
already present at the time of the colectomy.68
Ault et al. described a series of five patients who developed
adenocarcinoma in the middle of the pouch.69 Al Sukhni et
al.71 estimated the risk of new cancer or recurrence in the
pouch or rectal cuff in patients with UC who had undergone
stapled ilea pouch-anal anastomosis versus mucosectomy
with hand-sewn anastomosis. They noticed that performing a
stapled ileal pelvic anal anastomosis does not appear to be
inferior to mucosectomy and hand-sewn anastomosis in
preventing cancer.
3.1.2. Dysplasia
Development of dysplasia could precede or appear con-
currently with carcinoma. A number of descriptions havedealt with the development of dysplasia in the pouch and
cuff.
Das et al. noticed that dysplasia in the ileal reservoir is
rare and was associated with histological type C changes
with an atrophic mucosa, unremitting pouchitis, and the
presence of sclerosing cholangitis. They reported 17 adeno-
carcinomas: 9 in the residual anorectal mucosa, 7 in the
reservoir, and 1 of their own. Since the time intervals from
the onset of UC and from the restorative proctocolectomy to
the development of cancer were 120 to 528 and 16 to
216 months respectively, they proposed that cancer
appeared to be related to the duration of UC itself and not
to the interval from operation.72
It has been suggested that patients with UC and a
long-standing ileoanal pouch anastomosis could develop
persistent severe mucosal atrophy which is a risk factor for
neoplastic transformation of the pouch mucosa. Gullberg et
al.73 studied 7 patients with ileoanal pouch anastomosis and
persistent mucosal atrophy (type C) and 14 controls with
slight atrophy (type A). Dysplasia was found in 71% (5 out of 7
patients) in the type C group compared to none in the type A
group (P b 0.001).
In another study referring to 138 patients who underwent
restorative proctocolectomy for UC (n = 118), familial
adenomatous polyposis (n = 10), Crohn's colitis (n = 2), and
indeterminate colitis (n = 8), dysplasia was found in the
colectomy specimens in 22 (18.3%) and invasive cancer in 8
(6.7%) of them. Median interval between proctocolectomy
and pouch biopsy was 5.4 years. Indefinite dysplasia was
found in only one out of 138 patients.74 Another study
suggested that the development of dysplasia in ileal pouches
is probably a rare event within 15–20 years of pouch
surgery. In this 10-year study, the authors found only one
case of multifocal, low-grade dysplasia (0.9%). Aneuploidy
was found in this one and two more patients.75
In a group of 276 patients who had undergone restorative
proctocolectomy between 1984 and 2009 Banasiewicz et al.76
found that pouchitis significantly increased the risk of low
grade dysplasia (OR 13.48, 1.48–122.86 95% CI, P = 0.021);
the time period preceding dysplasia was commonly shorter in
patients with pouchitis, but three patients developed low
grade dysplasia after 7, 15 and 16 years progressing to high
grade dysplasia in the following 6–8 years. This observation
points out the importance of long term follow-up, as dysplasia
may occur many years after IPAA.
Three more studies also suggested that the risk of the
development of dysplasia in the pouch is rather low.
Börjesson et al. suggested that the risk of developing either
dysplasia or cancer in the ileal pouch mucosa after
restorative proctocolectomy for UC is low even after a long
follow-up.77 In their study of 45 patients, who had been
operated on with an ileo-anal pouch anastomosis with a time
interval from the start of the disease until the end of
follow-up of 24.8 years, no high-grade dysplasia or invasive
carcinoma was found.
Similar results were described by Veress et al.78 Among
87 patients who were followed up for at least 6.3 years,
low-grade dysplasia occurred in 3 patients with type C
response. Finally, Hulten et al. found no case of high-grade
dysplasia or invasive carcinoma in their study of 40 patients
being previously operated on for UC after a mean follow-up
of 30 years.79 It is of interest that in this study there was full
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 agreement between the two groups of pathologists regard-
ing the absence of high-grade dysplasia and invasive
carcinoma in the examined biopsies, although a significant
disagreement in the frequency of low-grade and indefinite
categories of dysplasia was seen.
ATZ dysplasia after ileal pouch-anal anastomosis is
infrequent, most common in the first 2–3 years postopera-
tively, and may apparently disappear on repeated biopsy.
O'Riordain et al. followed 210 patients for a median time of
6.4 years and found 7 patients (3%) who developed dysplasia
in the ATZ.80 It is of interest that in 5 out of these 7 patients,
dysplasia “disappeared” during further follow-up.
Patients with UC and primary sclerosing cholangitis with
an ileal pouch are more prone to develop mucosal atrophy in
the pouch (type C changes) and have a higher risk of
neoplastic transformation in the pouch mucosa than patients
with UC without sclerosing cholangitis. Stahlberg et al.
studied 16 patients with UC and primary sclerosing
cholangitis and 16 matched patients with UC without
sclerosing cholangitis. Moderate or severe atrophy was
more common in UC and primary sclerosing cholangitis
compared to the control group (8 vs 2 pts). Low-grade
dysplasia was found in 3 patients with sclerosing cholangitis
and in 2 of the controls.81
A large study estimated the risk of the development of
dysplasia in the ATZ and the outcome of a conservative
management policy for ATZ dysplasia, with at least a 10-year
follow-up after ileal pouch-anal anastomosis. One hundred
and eight patients undergoing ATZ-sparing ileal pouch-anal
anastomosis were submitted to anal transitional zone
biopsies for at least ten years postoperatively. In 8 patients
ATZ dysplasia posed the risk of dysplasia being significantly
associated with preoperative diagnosis of cancer or dyspla-
sia. Dysplasia was of high-grade in two patients, and
low-grade in six patients. No association with age, gender,
IBD duration and extent of IBD was found.82
In conclusion, the available data support the assumption
that the development of carcinoma and dysplasia in the
pouch and rectal cuff or ATZ of patients with UC undergoing
ileo-anal pouch anastomosis is a reality. However, the risk of
the appearance of dysplasia seems to be low even many
years after the creation of the pouch.163.2. Pathogenesis
The pathogenesis of pouch carcinoma is largely unknown.
The most relevant proposed pathway is for the ileal pouch
mucosa to go through the adaptational changes, then to
proceed through the stages of inflammation (chronic
pouchitis), dysplasia (of low and high degree), and subse-
quently to adenocarcinoma. In many of the available
studies, however, the dysplasia–cancer sequence is incon-
clusive since the carcinoma might have developed from the
ileal mucosa itself or from residual rectal mucosa.
In a study aiming to evaluate the prevalence and
spectrum of inflammatory changes in the ileum in patients
with UC, 200 consecutive patients were evaluated for a
variety of pathologic features in the ileum and colon.
Overall, 34 out of 200 (17%) UC patients had inflammatory
changes in the ileum; 32 of these 34 patients (94%) had
pancolitis, which was significantly higher than the rate ofpancolitis (39%) in patients without ileal disease (N = 166)
(P b 0.001). The presence of inflammatory changes in the
ileum had no effect on the prevalence of pouch dysplasia or
cancer.83
Other pathogenetic mechanisms could be related to the
residual diseased mucosa left behind. However, Kariv et al.,
in a study of 3203 patients who underwent restorative
proctocolectomy with ileo-anal pouch anastomosis, found
that mucosectomy did not protect against pouch neoplasia.
In fact, 38 patients (1.2%) developed pouch neoplasia (11
adenocarcinoma, 1 lymphoma, and 2 squamous cell carci-
noma) with cumulative incidence of 1.3% at 10, and 5.1% at
25 years respectively. Only the presence of preoperative
neoplasia was associated with an increased risk of pouch
neoplasia and thus, the performance of mucosectomy was
not protective against the development of carcinoma.84
In conclusion, the available data are in favor of the
assumption that although most of pouch neoplasia follows
the chronic inflammation–dysplasia–cancer sequence, this
is not the rule in all cases. Chronic inflammation, severe
atrophy and previous diagnosis of cancer or dysplasia in the
large bowel are probably involved in the pathogenesis of
cancer appearing in the pouch.3.3. Risk factors
Several risk factors for the development of pouch-related
cancer have been considered.3.3.1. Dysplasia or cancer in the resected colon
These features increase the likelihood of subsequent
dysplasia. Most studies reported this finding.75,82,85 Tsunoda
et al.85 reviewed 118 patients with colitis: 2 out of 3 patients
with dysplasia were in a subgroup of 8 patients who had a
carcinoma in the large bowel. Also Remzi et al.82 found an
association between dysplasia in the ATZ and cancer or
dysplasia in the postoperative specimen, concluding that the
carcinoma poses the anal mucosa at high risk. The presence
of pre-existing dysplasia or cancer seems to be the most
important predisposing risk factor for the development of
neoplasia after ileo-anal pouch anastomosis, as 54–70% of
patients developing pouch-related cancer had a dysplasia or
cancer which was identified preoperatively or that was
found in the operative specimen.72,753.3.2. Interval from the diagnosis of UC
The risk of pouch cancer, as well as that of colorectal
cancer in UC, increases with time, probably in a similar
fashion70,76,86 and it is related to the anatomical extent of
the disease in preoperative specimen.85 Cancer is reported
to occur at least 10 years after UC onset.70,72 Disease onset
is definitively more important than interval from IPAA and is
to be considered when considering surveillance.3.3.3. Pouchitis and mucosal changes
Inflammation and mucosal changes seem to play a role in
pouch-related carcinogenesis. As discussed above, patients
with unremitting pouchitis and type C atrophic changes have
the highest risk of pouch dysplasia.
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Coull et al.87 followed up for a median of 56 months 110
patients who underwent stapled ileo-anal pouch anastomosis
for UC by cuff surveillance biopsies under general anesthesia;
p53 was performed for each of most recent cuff biopsy.
Neither carcinomas developed nor dysplasia or carcinoma was
observed in any cuff biopsy during the follow-up period. The
authors concluded that p53 is not useful in surveillance of cuff
biopsies from patients who have undergone ileo-anal pouch
anastomosis for UC. Several markers of inflammation are over
expressed in ileal pouch, even without the endoscopic
evidence of pouchitis.88 Vento et al.89 studied 42 patients
with chronic pouchitis by endoscopy with biopsies performed
after a median of 8.3 years from ileo-anal pouch anastomosis.
No p53, abnormal DNA flow cytometry and dysplasia were
observed. The authors concluded that patients undergoing
ileo-anal pouch anastomosis for UC should not be intensively
followed up with endoscopy during the first 10 years after
surgery, on condition that hand-sewn anastomosis with
mucosectomy was accurately performed. by guest on February 23, 2016
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 3.3.5. Hand-sewn plus mucosectomy versus stapled
anastomosis
Mucosectomy does not eliminate the potential for
neoplastic transformation. In fact, studies reported cases
of adenocarcinoma after ileo-anal pouch anastomosis occur-
ring in patients who underwent mucosectomy.70,90 Residual
microscopic mucosal rectal islands have been reported in
20% of patients, so that a cancer can develop between the
pouch and the muscle layers.
Debate exists as to the benefits of performingmucosectomy
in pouch surgery. Tsunoda et al.85 found dysplasia in 3 patients
within the ATZ, but 2 out of 3 were in a subgroup of 8 patients
who had a carcinoma in the large bowel. Remzi et al.82 studied
dysplasia of ATZ performing several biopsies in 289 pouch
patients for a minimum follow-up of 10 years. ATZ dysplasia
developed in 8 patients 4–123 months after surgery (median
9 months). The risk was associatedwith a cancer or dysplasia in
the postoperative specimen. Four patients with low grade
dysplasia treated expectantly showed no subsequent dysplasia.
Coull et al.91 studied 136 patients for 56 months and
showed no evidence of dysplasia in cuff biopsies. In 113
patients at 2.5 years of mean follow-up Thompson-Fawcett
et al.92 found no evidence of neoplastic change in 457 biopsy
specimens. Although stapled IPAA seems to achieve similar
oncological outcomes similar to that of mucosectomy,71,93
some authors72,89 recommended mucosectomy as a safer
alternative. Functional concerns are to be considered too,
but results are similar also in terms of function when the
surgeon avoids excessive or prolonged dilation of the
sphincters during mucosectomy.3.3.6. Extraintestinal manifestations
Preoperative extraintestinal manifestations seem to be
associated with higher risk of developing pouch-related
malignancies. Interestingly, patients with extraintestinal
manifestations are more likely to develop pouchitis and type
C changes of the pouch.94–96 The likelihood of developing
pouchitis or pouch dysplasia is higher in UC patients with
primary sclerosing cholangitis regardless of the severity of
liver disease.81,943.4. Surveillance and diagnosis
It early became apparent that restorative proctocolectomy
does not completely abolish the risk of neoplasia of the pouch.
Moreover, since not all pouch carcinomas follow the chronic
inflammation–dysplasia–cancer sequence, the regular pouch
endoscopywith biopsy, representing the current gold standard
for surveillance, does not seem suitable for all cases.
Moreover, because pouch endoscopy with biopsies still misses
dysplasia, there is a debate on the optimal need and time
interval of routine endoscopic surveillance. Subsequently,
many authors suggest that surveillance endoscopy could be
applied in patients at risk, such as those with a pre-colectomy
diagnosis of UC-associated neoplasia, primary sclerosing
cholangitis, type C ileal mucosal changes and unremitting
pouchitis.70,78,97 If repeated biopsies confirm persistent
dysplasia, mucosectomy with perineal pouch advancement
and neo-ileal pouch-anal anastomosis are recommended.82
The optimum time interval for routine surveillance is
unknown. Ault et al. suggest that patients with long-standing
ileal pouches might benefit from routine surveillance of the
pouch as often as every six months, which can be quickly and
easily performed in the office using flexible endoscopy.69
Das et al. suggest that a surveillance program should begin
10 years from the onset of the disease by taking multiple
biopsies of the ileal reservoir and the anorectal mucosa
below the ileo-anal anastomosis.72
However, some authors suggest that routine pouch
surveillance with biopsies may not be warranted.74 Um et
al. proposed that there is little evidence to support routine
biopsy of the ileal mucosa or the ATZ except in patients with
predisposing factors.90 Little evidence to support routine
biopsy of the ileal mucosa in UC patients was also proposed
by both Herline et al.98 and Borjesson et al.77
When performed, 4 quadrant biopsies should be taken
from the upper and lower pouches, and a further 4 biopsies
targeted at just below the anastomosis, in the ATZ.
Anorectal mucosal biopsies should be taken under anesthe-
sia, if necessary, as this area is sensitive. Biopsies should not
include staple line, as their features of inflammation could
lead to an incorrect diagnosis of pouchitis.
When available, the use of high magnification chromoscopic
pouchoscopy is recommended. Hurlstone et al.99 reported that
it is a useful predictor of ATZ and cuff anatomy, allowing
accurate biopsy targeting. This approach is to be encouraged,
as the follow-up of patients with regard to the possible
development of dysplasia is likely to be improved, as the
technique has demonstrated morphological differences be-
tween ATZ, anal columnar epithelium and the pouch mucosa.
In conclusion, there is no general agreement concerning
the need for regular surveillance in these patients. However,
the majority of reports suggest that regular endoscopic
follow-up must be applied in patients at risk, such as those
with a pre-colectomy diagnosis of UC-associated neoplasia,
primary sclerosing cholangitis, patients with type C ileal
mucosal changes, and patients with unremitting pouchitis.3.5. Survival
There are no data concerning the survival of patients
undergoing ileo-anal pouch anastomosis who developed
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 pouch carcinoma, a fact that could be easily explained since
the number of reported cases is quite small for drawing firm
conclusions. However, from the case-reports that appeared
in the literature it seems that the survival of these patients
does not differ from patients with large bowel cancer being
developed on the ground of IBD. Nevertheless, although the
natural history and prognosis of pouch dysplasia are not
clear, the mortality rate associated with pouch cancer, once
diagnosed, appears to be high.97
Regarding the influence of the kind of anastomosis on the
survival of the operated patients, it seems that stapled
ileal-pelvic anal anastomosis is not inferior to mucosectomy
and handsewn anastomosis. A retrospective analysis of
patients with UC associated with colorectal dysplasia or
cancer, who underwent ileal-pouch anal anastomosis either
stapled (n = 59) or handsewn (n = 22), revealed that 52 had
dysplasia and 29 had colorectal cancer at the time of
surgery. During a median follow-up time of 6.3 years, nine
patients died (11%). Both colorectal cancer-related deaths
were in patients with hand-sewn anastomoses. However, the
overall 5-year survival between the two groups did not
significantly differ.71 If repeated biopsies confirm persistent
dysplasia, an ATZ excision with neo-ileal-pouch anal anasto-
mosis is recommended.80
4. Anal and fistula cancers
4.1. Epidemiology
Anal cancer is rare, with an annual incidence of 2 cases per
100,000100 There does not appear to be an excess risk in
patients with IBD. One of the largest case series examining
the incidence in patients with IBD followed 9602 patients for
a cumulative 99,229 years; 1.3 cases were expected,
whereas two were discovered.101
However, severe complicated perineal CDmay increase the
risk for anal cancer. Five anal cancers were reported from a
cohort of about 1250 patients seen at St Mark's Hospital,
London between 1940 and 1992. All had long-standing severe
anorectal disease, with strictures, abscesses, fistulae and
proctitis.102 They were followed up for a mean duration of
18 years (22,500 patient years). Less than one patient would
be expected to have developed anal cancer, therefore five
cases suggest that there may be an association between
complex perianal CD and anal malignancy, although this
conclusion is confounded by referral bias as St Mark's Hospital
is a tertiary referral center. Others have reported carcinoma
associated with anorectal fistula103–106 which is supported by
a higher rate of oncogenic HPV serotypes in sporadic anal
fistula and fissures. This could facilitate high risk HPV
serotypes access to the epithelium.103 A Swedish study
suggested anal cancer occurs at an earlier age and presents
at a more advanced stage in CD patients.107
4.2. Pathogenesis
Squamous cell cancer accounts for themajority of cases of anal
cancer, arising from the transitional or squamous cell mucosa.
Adenocarcinoma, melanoma and rarely sarcoma can occur.
Anal squamous cell carcinoma is strongly associated with
human papilloma virus infection. As with cervical cancer, HPV16 and HPV 18 are the most frequently associated oncogenic
serotypes. Anal HPV infection occurred in 50% of a cohort of
sexually active women over one year, with more than half
spontaneously clearing the infection within one year.108 About
1/3 of infections are with oncogenic HPV strains. The
prevalence and clearance of anal HPV infection are similar in
heterosexual men. However, men who have sex with men have
more persistent infection, and a higher proportion of oncogenic
serotypes, particularly with multiple partners and following
receptive anal intercourse.109 Consequently the rate of anal
cancer is much higher in men who have sex with men,
particularly those with HIV infection where a rate of 131/
100,000 person years has recently been reported.110
In conclusion, the available data indicate that HPV is
responsible for the majority of anal cancers in IBD patients,
which is a special interest from a preventive point of view.
4.3. Risk factors
The high rate in HIV+ men who have sex with men may
represent high risk behavior, however it does appear that
chronic immune suppression (CD4 b 500 × 106/L) predisposes
to progression to high grade anal-intraepithelial neoplasia
(AIN) and anal cancer.111 Lymphoma and squamous cell cancer
occur more frequently with immune-suppression following
solid organ transplantation. The rate of vulvar and anal
cancers has been reported to increase 100-fold following renal
transplantation.112 The effect of immune suppression on anal
cancer rates in IBD is largely unknown. The CESAME cohort113
did not demonstrate an association between thiopurine use
and anal cancer in IBD patients although the crude risk in the
subset of patients with perianal CD exposed to thiopurines was
0.42 per 1000 patient years, which is much higher than that
expected. The TREAT and the ENCORE registries have not
demonstrated an excess of anal cancers in patients treated
with Infliximab.113,114
4.4. Diagnosis
Screening for AIN using high resolution anoscopy has been
recommended in high risk individuals, such as HIV+ men who
have sex with men, women with high grade cervical dysplasia,
those known to have AIN orwith immune suppression following
solid organ transplantation. Treating AIN can prevent its
progression. Anal cancer should be suspected in IBD patients
with exuberant perianal granulation tissue, persistent ulcer-
ation, or anorectal pain or bleeding. The diagnosis is often
delayed in IBD, due to similar nonspecific symptoms, with
cancer assumed to be a benign stricture.
In conclusion, anoscopy represents the diagnostic tool of
choice in daily clinical practice that should be performed if
the patient develops suspicious symptoms.
4.5. Treatment
Sporadic anal squamous cell cancer usually can successfully
be treated with chemo-radiation, and there is no reason to
suspect whether treatment modalities should change in
patients with IBD, particularly as treatment of rectal cancer
in IBD patients with chemo-radiation has similar outcomes
for comparable stages of disease.115 However, surgical
27Non-colorectal intestinal tract carcinomas in inflammatory bowel diseaseresection may be required due to the additional burden of
longstanding complicated perianal CD.116,117
In summary, multimodal treatment of anal cancer in IBD
is similar to that in sporadic cancer but at least proctectomy
in CD, or total colectomy in UC, may be required depending
on disease extent. Survival outcomes seem to be the same as
in sporadic non-IBD cancer for the corresponding stage.
Overall, the prognosis is often poor due to a delay in
diagnosing anal cancer in chronic perianal disease.104Text Box: Key steps that can be taken to address current
knowledge gaps on non-colorectal intestinal tract carci-
nomas in inflammatory bowel diseasehttp://e
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 • Establishment of international case–control stud-
ies and disease registries to elucidate risk factors
and natural history
• Testing of new diagnostic modalities for small
bowel adenocarcinoma in Crohn's disease, such as
positron emission tomography and double balloon
enteroscopy
• Determination of optimum surveillance method and
schedule in patientswith ileo-anal pouch anastomosis by guest on February 23, 2016
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